Errant epitopes from arginine methylated SARS-CoV-2 proteins predisposing to autoimmune diseases.
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 177696
Grant search
Key facts
Disease
COVID-19Start & end year
20212022Known Financial Commitments (USD)
$246,781.5Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
Stéphane RichardResearch Location
CanadaLead Research Institution
Lady Davis Institute for Medical ResearchResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Drugs that can inhibit SARS-CoV-2 replication are urgently needed besides vaccines. The drugs can target the variants while vaccines provide limited immunity against only 1 protein, namely Spike. Our data show that viral proteins are modified post-translationally on arginine (methyl arginines) by protein arginine methyltransferases. This modification is necessary for the virus to suppress the anti-viral response and allow viral replication. We have shown that the N protein is arginine methylated and this is necessary for its function. Actually it is known that we develop antibodies against N protein, as it is very immunogenic. In addition, there are mutations in a key arginine residue in B.1.17 variant. In this proposal, we aim to understand how the methylated viral proteins are recognized by the immune system and if we will develop in the future autoimmune diseases because of this.